Abstract
Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.
Keywords: HDAC, Histone deacetylase inhibitors, Selectivity, Anti-cancer agents, aminobenzamides, cyclic peptides, yeast HDACs, C-terminus, bone homeostasis, Sirtuins
Anti-Cancer Agents in Medicinal Chemistry
Title: Selective Histone Deacetylase Inhibitors
Volume: 12 Issue: 3
Author(s): Huili Pan, Jiangying Cao and Wenfang Xu
Affiliation:
Keywords: HDAC, Histone deacetylase inhibitors, Selectivity, Anti-cancer agents, aminobenzamides, cyclic peptides, yeast HDACs, C-terminus, bone homeostasis, Sirtuins
Abstract: Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.
Export Options
About this article
Cite this article as:
Pan Huili, Cao Jiangying and Xu Wenfang, Selective Histone Deacetylase Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228814
DOI https://dx.doi.org/10.2174/187152012800228814 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of ERKs/RSK2 Signaling in Cancers
Current Pharmaceutical Design Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued) Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis
Current Respiratory Medicine Reviews Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Multifunctional Thio-Stabilized Gold Nanoparticles for Near-Infrared Fluorescence Detection and Imaging of Activated Caspase-3
Current Analytical Chemistry Characterisation of Small Supernumerary Marker Chromosomes (sSMC) in Human
Current Genomics Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets Evaluation Method of Mechanical Properties of Living NSCLC Cells Based on Nano-indentation
Current Nanoscience Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Preface: MicroRNA: Short but not Small
MicroRNA Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry PARP Inhibitors in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery